CXCR4 antagonists for the treatment of HIV infection
AssigneeEmory University
InventorsHyunsuk Shim, Dennis C. Liotta, James P. Snyder, Weiqiang Zhan, Zhongxing Liang
Life of this patent
Estimating the term…
Abstract
The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor, and in particular to inhibit viral entry of certain viruses. Certain compounds in particular can reduce entry of immunodeficiency virus (HIV) into a cell while not reducing the capacity of stem cells to proliferate, and therefore can be useful for long term treatment regimes. The compounds are useful in particular in the treatment or prevention of HIV infections.
Claims3
A compound of Formula I, or a pharmaceutically acceptable salt or ester thereof:
- each K is independently N;
- Each Q, T, U, V, W, X, Y and Z are each independently H, R, acyl, F, Cl, Br, I, CN, OH, OR, NH2, NO2, NHR, NR2, SR, S2R, S—NHR, S2—NHR, S—NRR', S2—NRR', NHacyl, N(acyl)2, CO2H, CO2R, where R and R′ are independently selected from straight chain, branched or cyclic alkyl or aralkyl, as well as aryl and heteroaryl groups;
- R1 and R2 are hydrogen;
- R3, R4, R5 and R6 are independently selected from H, straight chain, branched or cyclic alkyl, aralkyl, aryl heteroaryl, acyl and imidolyl groups.
A compound of structure XVI, or a pharmaceutically acceptable salt thereof:
Dependencies are inferred from the claim text.